Post-occlusive Reactive Hyperemia and Basal-cell Carcinoma
NCT01455363 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2025-11-24
Summary
The investigators aim to test the hypothesis and to proof thank to laser speckle contrast imaging that post-occlusive reactive hyperemia (PORH) can be induced through a tumor, in this case, through a basal cell carcinoma, which will be used as a model of study of tumor vasculature.
This new concept of tumor perfusion artificial increase could be used in the future for malignant tumors treatment, in order to increase tumor mean oxygen partial pressure (thus decreasing tumor hypoxia, hallmark of malignant tumors) during cancerology therapies, like radiotherapy and/or chemotherapy, and increase their efficacy.
This clinical trial will use skin flap model for trunk and facial basal cell carcinoma (BCC), with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
Conditions
- Carcinoma, Basal Cell
Interventions
- PROCEDURE
-
BCC surgery
This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
- OTHER
-
Tourniquet ischemia
In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
- OTHER
-
Laser speckle imaging
During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
Sponsors & Collaborators
-
Institut Curie
lead OTHER
Principal Investigators
-
GUILHARD Thierry, MD · INSTITUT CURIE - HOPITAL RENE HUGUENIN
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-06-30
- Primary Completion
- 2011-10-31
- Completion
- 2011-10-31
Countries
- France
Study Locations
More Related Trials
-
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
NCT04389112 ·Status: UNKNOWN ·Phase: NA
-
Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
NCT05608902 ·Status: COMPLETED
-
High Intensity Focused Ultrasound (HIFU) Treatment of Basal Cell Carcinoma
NCT05698706 ·Status: UNKNOWN ·Phase: NA
-
Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas
NCT02125669 ·Status: COMPLETED ·Phase: NA
-
RCT Treatment Versus Non Treatment of Low-risk BCCs in Elderly
NCT05110924 ·Status: TERMINATED ·Phase: NA
-
Evaluation of the Efficiency and Economic Impact of LC-OCT (Line-field Confocal Optical Coherence Tomography) for the Diagnosis and Management of Basal Cell Carcinomas
NCT06271603 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Recurrence Rate and Esthetic Outcome After Excision of Basal Cell Carcinomas Excluded From Trial NCT00515970
NCT00639652 ·Status: UNKNOWN
-
Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue
NCT07311070 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
The Role of Melanocyte in Basal Cell Carcinoma
NCT02576769 ·Status: UNKNOWN
-
Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
NCT02667574 ·Status: COMPLETED ·Phase: PHASE2
-
Nuclear and Near-Infrared (NIR) Imaging in Melanoma
NCT01295931 ·Status: COMPLETED ·Phase: PHASE1
-
Added Value of OCT for Diagnosing Recurrent BCC After Non-invasive Treatment
NCT05581342 ·Status: COMPLETED ·Phase: NA
-
Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser
NCT02270645 ·Status: COMPLETED ·Phase: NA
-
Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs
NCT06014619 ·Status: ACTIVE_NOT_RECRUITING
-
One-stop-shop Study for Treatment of Basal Cell Carcinoma Using Reflectance Confocal Microscopy
NCT02285790 ·Status: COMPLETED ·Phase: NA
-
Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes
NCT02310451 ·Status: COMPLETED ·Phase: NA
-
Reflectance Confocal Microscopy to Diagnose BCC
NCT03509415 ·Status: COMPLETED
-
Retrospective and Prospective Observational Study in Patients With Advanced Basal Cell Carcinoma
NCT06309836 ·Status: RECRUITING
-
Feasibility and Functionality of fPAM Imaging in Melanoma
NCT00776945 ·Status: TERMINATED
-
Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1
NCT05856565 ·Status: RECRUITING
-
Precision Medicine for L/GCMN and Melanoma 2
NCT06605443 ·Status: RECRUITING
-
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
NCT01631331 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Impact of Obstructive SAS on Metastatic Potential of Cutaneous Melanoma
NCT02699918 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma
NCT02956889 ·Status: TERMINATED ·Phase: PHASE2
-
New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management
NCT05324202 ·Status: UNKNOWN ·Phase: NA